TG and Rhizen to co-develop PI3K inhibitor
This article was originally published in Scrip
Executive Summary
New York-based TG Therapeutics has licensed a phosphoinositide-3-kinase (PI3K) inhibitor of the delta pathway from Rhizen Pharmaceuticals of Switzerland that it hopes to position as one of the first PI3K therapies on the market for haematological malignancies and autoimmune disorders.
You may also be interested in...
Alembic Remains Upbeat Despite Rhizen Setback
Disappointment for Alembic-backed Rhizen after partner TG Therapeutics takes Ukoniq off the US market amid wider regulatory scrutiny around the PI3K inhibitor class of drugs. The Indian firm, however, remains upbeat about the US business, which saw significant growth in the fiscal fourth quarter and has 15-plus launches lined up.
Setback For Alembic-backed Rhizen After Concerns Over PI3K Inhibitors
Disappointment for Alembic-backed Rhizen after partner TG Therapeutics takes Ukoniq off the US market amid wider regulatory scrutiny around the PI3K inhibitor class of drugs. The Indian firm, however, remains upbeat about the US business, which saw significant growth in the fiscal fourth quarter and has15-plus launches lined up.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.